People/News Test

Executives

Andrew Macan

Andrew Macan

Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary

Andrew Macan

Andrew Macan

Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary

W. Andrew Macan has served as Neuronetics’ Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary since January 2020.

Prior to joining Neuronetics, Mr. Macan was Senior Vice President, General Counsel and Corporate Secretary of U.S. Silica Holdings, Inc., a Russell 2000 diversified minerals company, from October 2018 until January 2020. He served in roles of increasing responsibility with Axalta Coating Systems, LLC, from October 2013 until October 2018, most recently as General Counsel and Chief Compliance Officer, Americas, and The Chubb Corporation, from October 2003 until October 2013, including as Vice President, Corporate Counsel and Secretary for over 8 years.

Mr. Macan began his career in private practice at Ballard Spahr LLP and Dechert LLP. He earned a B.A. in Government from Franklin & Marshall College and his J.D. from Emory University School of Law with distinction and Order of the Coif.

Bruce J. Shook

Bruce J. Shook

Bruce J. Shook

Bruce J. Shook

Bruce Shook is a medical device executive with more than 30 years of industry experience, including multiple early stage ventures focused on opportunities in cardiac surgery, cardiology, neurosurgery, psychiatry and vascular disease. He serves as Director, President and CEO for both Intact Vascular and Vesper Medical. Intact Vascular is a privately held medical technology company that develops and commercializes vascular scaffolding technology for the treatment of peripheral arterial disease. The company is currently marketing the Tack Endovascular System® in the U.S. and Europe. Vesper Medical was spun out of Intact Vascular in late 2016 and is developing a novel family of venous stents designed to treat deep venous disease.
Prior to Intact Vascular and Vesper Medical, Mr. Shook was co-founder, Director, President and CEO of Neuronetics, Inc., [NASDAQ: STIM] a publicly traded device company that markets a non-invasive brain stimulation technology for the treatment of depression.
Previously, Mr. Shook was co-founder, Director, President and CEO at Neuron Therapeutics, a venture-backed company developing a drug/device product for the treatment of CNS disorders, and President of Abiomed [NASDAQ: ABMD], where he obtained PMA approval for the first FDA-approved ventricular assist device. Mr. Shook also developed cardiac pacing and anti-arrhythmia products at Cordis Corporation.
Mr. Shook holds advanced degrees in Biomedical Engineering and Business Administration from Columbia University and the MIT Sloan School of Management, respectively. He earned a B.S. degree in Chemical Engineering from Penn State University. Mr. Shook currently serves on the Board of Directors at Neuronetics, Venarum Medical, the Penn State Research Foundation (Vice Chairman) and Life Sciences Pennsylvania (Medical Technology Committee Chairman). He previously served on the Board of Directors at Surgiquest, Respicardia and CoTherix.

Cory Anderson

Cory Anderson

VP Clinical Affairs & Interim VP R&D

Cory Anderson

Cory Anderson

VP Clinical Affairs & Interim VP R&D

Cory Anderson joins Neuronetics with over 20 years of medical technology experience, along with deep executive leadership within medical device startup companies.

Most recently, Mr. Anderson served as Vice President, Business Development and Marketing (Corporate Officer) at Sebacia. During his time at Sebacia, he led phase IV clinical trials in five countries and strategically guided the company’s R&D pipeline. Prior to Sebacia, he was VP Business Development at The Innovation Factory (TIF, the incubator where Neuronetics started) and a Principal at Accuitive Medical Ventures (AMV, venture investor in Neuronetics). During his time at TIF and AMV, Mr. Anderson managed operations of two portfolio companies in the ophthalmic space, evaluated new business/investment opportunities, and supported investments in the portfolio of companies.

Prior to his time at TIF and AMV, Mr. Anderson held positions of increasing responsibility within Product Development and Marketing at Novoste Corporation where he developed products for interventional cardiology.

Mr. Anderson has been a board observer and investor in two successful exits of venture-backed companies: AqueSys (acquired by Allergan/AbbVie, NYSE: ABBV) and MyoScience (acquired by Pacira BioSciences, NASDAQ: PCRX).

Mr. Anderson holds Bachelor’s and Master’s degrees in Biomedical Engineering from Tulane University, and an MBA from Emory University. Mr. Anderson is an inventor on seven issued US patents and an author of two peer-reviewed papers and one book chapter.

Board of Advisors

Andrew Macan

Andrew Macan

Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary

Andrew Macan

Andrew Macan

Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary

W. Andrew Macan has served as Neuronetics’ Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary since January 2020.

Prior to joining Neuronetics, Mr. Macan was Senior Vice President, General Counsel and Corporate Secretary of U.S. Silica Holdings, Inc., a Russell 2000 diversified minerals company, from October 2018 until January 2020. He served in roles of increasing responsibility with Axalta Coating Systems, LLC, from October 2013 until October 2018, most recently as General Counsel and Chief Compliance Officer, Americas, and The Chubb Corporation, from October 2003 until October 2013, including as Vice President, Corporate Counsel and Secretary for over 8 years.

Mr. Macan began his career in private practice at Ballard Spahr LLP and Dechert LLP. He earned a B.A. in Government from Franklin & Marshall College and his J.D. from Emory University School of Law with distinction and Order of the Coif.

Bruce J. Shook

Bruce J. Shook

Bruce J. Shook

Bruce J. Shook

Bruce Shook is a medical device executive with more than 30 years of industry experience, including multiple early stage ventures focused on opportunities in cardiac surgery, cardiology, neurosurgery, psychiatry and vascular disease. He serves as Director, President and CEO for both Intact Vascular and Vesper Medical. Intact Vascular is a privately held medical technology company that develops and commercializes vascular scaffolding technology for the treatment of peripheral arterial disease. The company is currently marketing the Tack Endovascular System® in the U.S. and Europe. Vesper Medical was spun out of Intact Vascular in late 2016 and is developing a novel family of venous stents designed to treat deep venous disease.
Prior to Intact Vascular and Vesper Medical, Mr. Shook was co-founder, Director, President and CEO of Neuronetics, Inc., [NASDAQ: STIM] a publicly traded device company that markets a non-invasive brain stimulation technology for the treatment of depression.
Previously, Mr. Shook was co-founder, Director, President and CEO at Neuron Therapeutics, a venture-backed company developing a drug/device product for the treatment of CNS disorders, and President of Abiomed [NASDAQ: ABMD], where he obtained PMA approval for the first FDA-approved ventricular assist device. Mr. Shook also developed cardiac pacing and anti-arrhythmia products at Cordis Corporation.
Mr. Shook holds advanced degrees in Biomedical Engineering and Business Administration from Columbia University and the MIT Sloan School of Management, respectively. He earned a B.S. degree in Chemical Engineering from Penn State University. Mr. Shook currently serves on the Board of Directors at Neuronetics, Venarum Medical, the Penn State Research Foundation (Vice Chairman) and Life Sciences Pennsylvania (Medical Technology Committee Chairman). He previously served on the Board of Directors at Surgiquest, Respicardia and CoTherix.

Cory Anderson

Cory Anderson

VP Clinical Affairs & Interim VP R&D

Cory Anderson

Cory Anderson

VP Clinical Affairs & Interim VP R&D

Cory Anderson joins Neuronetics with over 20 years of medical technology experience, along with deep executive leadership within medical device startup companies.

Most recently, Mr. Anderson served as Vice President, Business Development and Marketing (Corporate Officer) at Sebacia. During his time at Sebacia, he led phase IV clinical trials in five countries and strategically guided the company’s R&D pipeline. Prior to Sebacia, he was VP Business Development at The Innovation Factory (TIF, the incubator where Neuronetics started) and a Principal at Accuitive Medical Ventures (AMV, venture investor in Neuronetics). During his time at TIF and AMV, Mr. Anderson managed operations of two portfolio companies in the ophthalmic space, evaluated new business/investment opportunities, and supported investments in the portfolio of companies.

Prior to his time at TIF and AMV, Mr. Anderson held positions of increasing responsibility within Product Development and Marketing at Novoste Corporation where he developed products for interventional cardiology.

Mr. Anderson has been a board observer and investor in two successful exits of venture-backed companies: AqueSys (acquired by Allergan/AbbVie, NYSE: ABBV) and MyoScience (acquired by Pacira BioSciences, NASDAQ: PCRX).

Mr. Anderson holds Bachelor’s and Master’s degrees in Biomedical Engineering from Tulane University, and an MBA from Emory University. Mr. Anderson is an inventor on seven issued US patents and an author of two peer-reviewed papers and one book chapter.

Janie Bates

Janie Bates

Vice President of Marketing

Janie Bates

Janie Bates

Vice President of Marketing

Janie Bates has served as the Company’s Vice President of Marketing since July 2019.
Ms. Bates has over 30 years of marketing leadership experience in medical device and consumer package goods industries. Prior to joining Neuronetics, she led Smith & Nephew’s Value Solutions business as the Vice President and General Manager from November 2017 to April 2019. Previous to that, Ms. Bates was Sr. Director of Global Marketing for the Kyphon business at Medtronic from February 2015 to November 2017. From April 2012 to February 2015, she provided strategic marketing consulting to start-up medical device companies.
In addition, from January 2010 to April 2012, Ms. Bates held the position of Chief Marketing Officer and VP of Innovation for Evergreen Packaging, a $1.7 billion company providing high-tech barrier packaging to the CPG industry. She also spent 10 years in various roles at Smith & Nephew, including Vice President of Marketing for medical therapies delivered in an office-based setting (now Bioventus). Her additional marketing leadership experience includes positions at Kraft Foods and Jimmy Dean Foods.
Ms. Bates has an MBA from the Anderson School at University of California Los Angeles and a BA in Economics from Dartmouth College.

NeuroStar® in the News